Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer. Issue 1 (January 2018)

• Record Type: Journal Article
• Authors: Leone, Gianmarco; Tucci, Marcello; Buttigliero, Consuelo; Zichi, Clizia; Pignataro, Daniele; Bironzo, Paolo; Vignani, Francesca; Scagliotti, Giorgio V; Di Maio, Massimo
• Is Part Of: Endocrine-related cancer. Volume 25:Issue 1(2018)
• Page Start: R1
• Page End: R9
• Publication Date: 2018-01
• Subjects: antiandrogen withdrawal syndrome -- prostate cancer -- bicalutamide -- enzalutamide -- abiraterone; Endocrine glands -- Cancer -- Periodicals; Endocrinology -- Periodicals; Cancer -- Endocrine aspects -- Periodicals; 616.9944005
• DOI: 10.1530/ERC-17-0355
• Languages: English
• ISSNs: 1351-0088

Abstract

Abstract : Antiandrogen withdrawal syndrome is an unpredictable event diagnosed in patients with hormone-sensitive prostate cancer treated with combined androgen blockade therapy. It is defined by prostate-specific antigen value reduction, occasionally associated with a radiological response, that occurs 4–6 weeks after first-generation antiandrogen therapy discontinuation. New-generation hormonal therapies, such as enzalutamide and abiraterone acetate, improved the overall survival in patients with metastatic castration-resistant prostate cancer, and recent trials have also shown the efficacy of abiraterone in hormone-sensitive disease. In the last few years, several case reports and retrospective studies suggested that the withdrawal syndrome may also occur with these new drugs. This review summarizes literature data and hypothesis about the biological rationale underlying the syndrome and its potential clinical relevance, focusing mainly on new-generation hormonal therapies. Several in vitro studies suggest that androgen receptor gain-of-function mutations are involved in this syndrome, shifting the antiandrogen activity from antagonist to agonist. Several different drug-specific point mutations have been reported. The association of the withdrawal syndrome for enzalutamide and abiraterone needs confirmation by additional investigations. However, new-generation hormonal therapies being increasingly used in all stages of disease, more patients may experience the syndrome when stopping the treatment at the time of disease progression, although the clinical relevance of this phenomenon in the management of metastatic castration-resistant prostate cancer remains to be defined.